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Summary  
Recent findings in monkeys indicate that excitatory amino 
acids such as glutamate are involved in the 
pathophysiological  cascade of MPTP (l-methyl-4-phenyl- 
1,2,3,6-tetrahydropyridine)- induced neuronal cell death. 
The neuroprotective effects of competitive and non- 
competit ive NMDA (N-methyl-D-aspartate) antagonists 
against MPTP toxicity support the hypothesis that NMDA 
receptor-mediated events are involved in the neurotoxic ity 
of MPTP. These results suggest that the clinical trial of 
NMDA antagonists in patients with Parkinson's disease 
should be performed. Further evidence obtained in animal 
models of Parkinson's disease indicates that both 
competit ive NMDA antagonists and AMPA (alpha-amino-3- 
hydroxy-5-methyl-4-isoxazolepropionate) antagonists show 
symptomatic anti-parkinsonian activity in combination with 
L-DOPA. Glutamate antagonists may therefore retard the 
progression and improve the symptomatology of Parkinson's 
disease. The l-amino-adamantanes amantadine and memantine 
have recently been shown to be non-competit ive NMDA 
antagonists and are widely used in Europe as anti- 
parkinsonian agents. Both compounds are likely to cause 
pharmacotoxic psychosis as an unwanted side-effect. 
Clinical trials are needed to test the eff icacy of the l- 
amino-adamantanes with respect to the progression of 
Parkinson's disease. 
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The biochemical changes observed in the substantia nigra of 
patients with Parkinson's disease such as impaired mitochondrial  
function, altered iron metabolism and increased lipid 
peroxidation emphasize the significance of oxidative stress and 
free radical formation in the pathogenesis of the disease (i, see 
Table i). Protection against such oxidative damage could be 
provided by scavengers of free radicals and anti-oxidants such as 
monoamine oxidase type B (MAO-B) inhibitors, alpha-tocopherol  
(vitamin E), ascorbic acid (vitamin C) and iron chelators. 
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Table 1 
Neuroprotect ive strategies in Parkinson's disease 
Biochemical alterations 
in the substantia nigra 
Possible neuroprotect ive 
therapies 
Formation of hydrogen peroxide 
Increased iron content 
Formation of toxic oxygen 
free radicals 
Alterat ion in the homeostasis 
of intracel lular calcium 
Excess activity of 
excitatory amino acids (?) 
MAO-B inhibitors 
(e.g. L-deprenyl) 
Iron chelators 
Free radical scavengers 
(e.g. vitamins C and E) 
Calcium entry blockers 
(e.g. nimodipine) 
Excitatory amino acid 
antagonists 
Excitatory amino acids and neurodeqenerat ion 
The amino acid L-glutamate is the major excitatory 
neurotransmitter in the mammalian central nervous system (2) and 
gates cationic channels that mediate fast excitatory synaptic 
responses. These channels also mediate neuronal death fol lowing 
excessive glutamate release in the central nervous system 
secondary to acute pathological events such as stroke and head 
trauma (see Table 2). Excessive activity of excitatory amino 
acids has been postulated to play a role in a variety of 
neurodegenerat ive diseases including Parkinson's disease (3). 
This hypothesis is based on findings showing neurotoxic 
propert ies of both L-glutamate (4) and substances excit ing the 
main ionotropic glutamate receptor subtypes, i.e. N-methyl-D- 
aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-  
isoxazolepropionate (AMPA) and kainate. The channels intrinsic to 
all subtypes conduct Na +, NMDA-gated channels also possess Ca 2+ 
conductivity that may play a role in neuronal plast ic i ty and 
neurotoxicity. Microinjections of many excitatory amino acids 
into various brain areas can produce an acute reaction that 
select ively destroys certain neurones in the area (5, 6). 
Table 2 
Pathological roles of glutamate 
Epi leptogenesis 
Acute neuropathological changes 
Hypoxia, Stroke, 
Hypoglycemia, Trauma, 
Exogenous toxins 
Chronic neuropathological changes 
Alzheimer's disease, Huntington's disease, 
Parkinson's disease, Motoneuron disease 
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Excitator7 amino acids and MPTP neurotoxicit7 
There is evidence indicating that excitatory amino acids are 
involved in the neurotoxic effects of MPTP. Systemic 
administrat ion of MPTP to humans and non-human primates causes 
parkinsonian motor deficits associated with a selective 
destruct ion of dopamine-containing neurones in the substantia 
nigra pars compacta and a marked reduction in striatal dopamine 
content (7. 8, 9, i0). Neurotoxicity appears to be due to the 
formation of l -methyl-4-phenylpyridinium ion (MPP+; ii, 12, 13) 
which is the result of the conversion of MPTP by MAO-B into the 
dihydropyr idinium species (MPDP ÷) which is converted non- 
enzymatical ly into MPP +. This compound is subsequently transported 
by the dopamine uptake process to accumulate within dopaminergic 
neurones and to be temporari ly stored in a releasable pool (14, 
15). The toxicity of MPP ÷ apparently occurs as the result of 
intraneuronal uptake by a mitochondrial carrier and inhibit ion of 
complex I of the mitochondrial respiratory chain (16). 
Excitatory amino acids such as glutamate appear to be 
involved in the pathophysiological cascade of MPTP/MPP+-induced 
neuronal death. It has been shown that MPP ÷ causes a release of 
glutamate and aspartate in the rat brain (17). Gutamate 
antagonists, which competit ively or non-competit ively block the 
NMDA subtype of receptor, protect dopaminergic nigral neurones 
against destruct ion by MPP ÷ injected directly into the substantia 
nigra pars compacta (SNC) of rats (18). Since rats are less 
sensit ive to MPP ÷ than primates, the doses of the toxin needed to 
produce brain damage are very high and could cause unspecif ic 
toxic effects (19). In the mouse, the non-competit ive NMDA- 
receptor antagonist (+)-5-methyl-10,11-dihydro-5H- 
dibenzo[a,d]cyclo-hepten-5,10- imine maleate (MK-801) has been 
shown to be ineffective in preventing the dopamine deplet ion 
induced by systemic administration of MPTP (20, 21). Recent 
studies in monkeys, however, have demonstrated that glutamate 
antagonists are able to modulate the neurotoxicity of MPTP. The 
competit ive NMDA antagonist 3-((±)-2-carboxypiperazin-4-yl) -  
propyl - l -phosphonic acid (CPP) protects tyrosine hydroxylase 
(TH)-positive neurones in the substantia nigra from degenerat ion 
induced by systemic treatment with MPTP in the common marmoset 
(22). The non-competit ive NMDA antagonist MK-801 prevents the 
development of the parkinsonian syndrome in the cynomolgus monkey 
(23) and protects nigral tyrosine hydroxylase-posit ive neurones 
in cynomolgus monkeys (23) and marmosets (24) from degenerat ion 
fol lowing the administration of MPTP. The neuroprotect ive action 
of competit ive and non-competit ive NMDA receptor antagonists 
against MPTP toxicity (see Table 3) supports the hypothesis that 
NMDA receptor-mediated events are involved in the neurotoxic ity 
of MPTP and MPP ÷. MPP ÷ interferes with mitochondrial  respirat ion 
and depletes cell energy resources (16). Neuronal energy 
deprivat ion could alter the normal functioning of cell membranes 
and cause a partial depolarization leading to a release of the 
voltage dependent Mg 2÷ block of NMDA receptor ion channels (25). 
Removal of the Mg 2+ block enables excitatory amino acids to excite 
their receptors persistently, to open the ion channels and to 
become neurotoxic (26). 
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Table 3 
Anti -glutamatergic neuroprotection 
fol lowing MPTP/MPP + administrat ion 
Species MPTP/MPP + Glutamate 
administrat ion antagonist 
Neuroprotect ive 
effects 
Mouse MPTP 20 mg/kg, 
2-hourly, 
4 times, i.p. 
Mouse MPTP 20 mg/kg, 
2-hourly, 
4 times, i.p. 
Rat MPP + focally 
into SNC 
Rat MPP ÷ focally 
into SNC 
Common MPTP 6 mg/kg, 
marmoset once, s.c. 
Common MPTP 2 mg/kg, 
marmoset daily, 5 days, 
s.c. 
MK-801 2.5 mg/kg, Partial protect ion 
3-hourly, twice, against neostr iatal  
i.p. dopamine reduction 
and no protect ion 
against reduced neo- 
striatal TH activity 
3 days after MPTP 
(20) 
MK-801 2.5 mg/kg, No protect ion 
4-hourly, 6 t imes,against neostr iatal  
i.p. dopamine reduction 
1 week after MPTP 
(21) 
CPP 0.i mmol/kg, Protection against 
MK-801 0.01 mmol/ neuronal loss in SNC 
kg, 4-hourly, 24 hours and 7 days 
6 times, i.p. after MPP + (18) 
MK-801 2.2 mg/kg, No protect ion 
4-hourly, 6 t imes,against nigral cell 
i.p. loss 7-11 days after 
MPP + (21) 
CPP 25 mg/kg, Protection of TH- 
4-hourly, 48 hrs, posit ive neurons in 
i.p. substantia nigra 
(22) 
MK-801 mg/kg Protect ion of nigral 
4-hourly, 7 days, TH-posit ive neurons 
s.c. and of neostr iatal  
[3H]mazindol binding 
sites 7 days after 
start of treatment 
(24) 
Cynomolgus MPTP 0.36 mg/kg MK-801 0.01 mg/kg Partial protect ion 
7 times a day 7 times a day 
for 5 days, for 5 days, 
i.v. i.v. 
monkey against neostr iatal  
dopamine reduction 
and protect ion of 
nigral TH-posit ive 
cells 12 days after 
start of treatment 
(23) 
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Excitatory amino acids and parkinsonism 
The neurotoxic effects of excitatory amino acids may be 
involved in the pathogenesis of Parkinson's disease (27). Other 
forms of parkinsonism have been linked with dietary consumption 
of toxic excitatory amino acids acting on dopaminergic cells in 
the substantia nigra. The amino acid 6-N-methylamin-L-alanine 
(BMAA) contained in flour made from the cycad Cycas circinal is 
has been proposed to be the cause of the amyotrophic lateral 
sclerosis-parkinsonism-dementia syndrome occurring in Guam and 
other South Sea islands (28). The excitotoxicity of BMAA can be 
blocked by AP5 or AP7, indicating an action on NMDA receptors 
(29). Concussive brain injuries are associated with increased 
extracel lular excitatory amino acid concentrations (30) and can 
cause nigrostr iatal degeneration and parkinsonism in boxers with 
dementia pugi l ist ica (31). 
The findings demonstrating neuroprotective effects of 
competit ive and non-competit ive NMDA antagonists in MPTP-treated 
monkeys suggest that the clinical trial of NMDA antagonists in 
patients with Parkinson's disease should be performed. The l- 
amino-adamantanes amantadine and memantine, which are in use as 
anti -parkinsonian drugs, have been shown to be non-competit ive 
NMDA antagonists (32). Memantine displaces [3H]-MK-801 in binding 
studies (32, 33) and has non-competit ive NMDA antagonist ic 
propert ies in functional models (34, 35). Whether or not these 
compounds have neuroprotective properties and whether they may be 
able to delay the progression of Parkinson's disease is unknown. 
If neuroprotective effects of NMDA antagonists can be shown in 
humans, then a novel strategy for the neuroprotective or even 
preventive therapy of Parkinson's disease could be available. 
Excitatory amino acids and akinesia 
The loss of dopamine in the striatum as a result of the 
neuronal degeneration in the substantia nigra pars compacta has 
been thought to be the major pathochemical correlate of the main 
symptoms of Parkinson's disease such as akinesia and rigidity 
(36). The discovery of dopaminergic deficiency in the basal 
ganglia led to the use of replacement therapies including L-DOPA 
treatment, dopaminergic agonists and the selective MAO-B 
inhibitor L-deprenyl. Dopamine has been shown in recent animal 
studies to be of less importance in the regulation of psychomotor 
functions than was previously believed. For example, a pronounced 
locomotor stimulation can be produced in mice depleted of 
monoaminergic stores following suppression of glutamatergic 
neurotransmission (37, 38). This finding raises the question of 
whether glutamatergic mechanisms are involved in the regulation 
of locomotor activity and in the motor symptoms observed in 
Parkinson's disease. 
There is increasing evidence that the dopaminergic nigro- 
striatal system and the strio-nigral GABA/substance P system are 
only one part of a motor loop system which is formed by the basal 
ganglia and the motor thalamus and receives information from wide 
cortical areas and projects to distinct premotor cortical areas 
(39). The degeneration of the dopaminergic nigro-str iatal  pathway 
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in Parkinson's disease results in profound changes within this 
motor loop. 
Both electrophysiological and neurochemical studies in MPTP- 
treated parkinsonian monkeys suggest that secondary increases of 
glutamatergic neurotransmission in the subthalamic nucleus, 
medial segment of the globus pall idus and substantia nigra pars 
reticulata are essential steps in the evolution of parkinsonian 
symptoms (40, 41). Enhanced glutamatergic activity is assumed to 
occur in the subthalamic nucleus due to a decreased GABAergic 
input from the lateral globus pallidus. Hyperact iv ity of the 
glutamatergic projection neurones in the subthalamic nucleus 
enhances activity in the basal ganglia output nuclei, i.e. the 
substantia nigra pars reticulata and the internal segment of the 
globus pallidus. The consequence of these alterations is a 
pathological  degree of tonic activity in the basal ganglia output 
system directed to the motor thalamus and brainstem (42). This 
simplif ied model of basal ganglia pathophysiology in Parkinson's 
disease suggests that anti-glutamatergic drugs may be of 
therapeutic benefit. Lesion of the subthalamic nucleus by focal 
injection of the neurotoxin ibotenic acid ameliorates 
parkinsonian symptoms in MPTP-treated green monkeys (40). The 
glutamate antagonist kynurenate reverses akinesia in the MPTP- 
treated common marmoset following focal injection into the medial 
pal l idum (43). These findings indicate that the selective 
reduction of glutamatergic overactivity may be an effective 
strategy for the treatment of Parkinson's disease. 
The val idity of the concept of glutamatergic hyperact iv i ty 
in Parkinson's disease and the potential for ant i -glutamatergic 
therapy are underl ined by studies with rodents demonstrat ing that 
the non-competit ive NMDA antagonist MK-801 (dizocilpine) 
stimulates locomotor activity in monoamine-depleted mice (37) and 
rats (44) and reverses neuroleptic- induced catalepsy in rats (45, 
46). The AMPA antagonist NBQX (6-nitro-7-sulfamoyl- 
benzo[f]quinoxal ine-2,3-dione) potentiates the action of L-DOPA 
in reserpinized rats (47) and in the 6-OHDA circl ing model (48). 
Initial experiments with monkeys rendered parkinsonian with MPTP 
failed to demonstrate an anti-parkinsonian action of MK-801 (49, 
50). Subsequent experiments with MPTP-treated common marmosets, 
however, showed that both the competit ive NMDA receptor 
antagonist CPP and the quisqualate receptor antagonist NBQX 
increase locomotor activity when administered with a threshold 
dose of L-DOPA (47, 48). 
Since the glutamatergic thalamo-cortical tract appears to be 
underactive in Parkinson's disease (40), systemic administrat ion 
of glutamate antagonists should aggravate parkinsonian symptoms. 
This is probably reflected in the reduction of locomotor activity 
observed in MPTP-treated monkeys following NBQX administered 
alone (48). However, the massive increase in locomotor activity 
obtained fol lowing the administration of L-DOPA plus NBQX or CPP 
(48) imply that stimulation of the deficient dopaminergic 
pathways in combination with inhibition of the glutamatergic 
systems has clear synergistic effects on locomotor activity. 
These findings in animal models of Parkinson's disease 
suggest that glutamate antagonists may be of benefit in the 
treatment of patients with the disease. A combined therapy with 
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L-DOPA and glutamate antagonists should al low a reduction of the 
L-DOPA dose and may postpone or prevent side-effects of long-term 
L-DOPA administrat ion (51). 
The only anti-glutamatergic drugs avai lable for the 
treatment of Parkinson's disease are the non-competit ive NMDA 
receptor antagonists amantadine and memantine, which have 
moderate anti -akinetic efficacy compared to dopamimetic 
substances (52). The action of memantine at the NMDA receptor 
might well explain its anti-parkinsonian activity, since the K i 
value of memantine is lower than the brain concentrat ion reached 
in the treatment of Parkinson's disease (32, 53). The f inding 
that the K i value of amantadine is about 20 times higher than that 
of memantine is compatible with the clinical experience that the 
mean dai ly dose of amantadine in the treatment of Parkinson's 
disease is about 5-10 times higher than that of memantine. 
Decreased glutamatergic function has been postulated to be a 
s ignif icant factor in the pathophysiology of schizophrenia (54). 
Ant i -g lutamatergic  treatment of Parkinson's disease carries 
therefore the risk of psychotic side-effects. Amantadine is known 
to have mild anti-akinetic effects in parkinsonian pat ients and 
psychosis is a frequent adverse reaction (52). The occurrence of 
pharmacotoxic psychosis has been examined fol lowing 
administrat ion of memantine in patients with Parkinson's disease 
(55). Parkinsonian subjects received memantine in addit ion to 
their usual anti -parkinsonian medication. Only one patient showed 
a mild improvement of his motor symptoms. The other three 
patients did not benefit from addit ional memantine 
administration. In two out of these three, however, memantine 
produced psychosis. Memantine administered in doses producing 
little or no anti -parkinsonian effects appears to be l ikely to 
cause pharmacotoxic psychosis. Whether or not competit ive NMDA 
antagonists or non-NMDA antagonists have similar s ide-effects 
remains to be examined in clinical trials. Because of possibly 
severe side-effects of glutamatergic antagonists in the treatment 
of akinesia, the development of partial glutamate antagonists 
could be an alternative strategy capable of producing anti- 
akinetic effects with only mild adverse reactions. 
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